Optimising Stroke Prevention in Older People with Atrial Fibrillation.

Active, not recruiting

• Conditions: Blood - Clotting disorders; Stroke; Atrial Fibrillation; Cardiovascular - Other cardiovascular diseases; Stroke - Ischaemic

• Registration Number: ACTRN12613000060741
• Lead Sponsor: niversity of Technology, Sydney

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2013-01-16
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Active, not recruiting
• Sex: All
• Target Recruitment: 500

Inclusion Criteria

GPs:
1. must be practicing in one site (i.e., general practice surgery), not across multiple sites or surgeries
2. must practice in the specified Divisions of General Practice
3. must provide informed written consent to participate in the study

Patients:
1. aged >= 65 years (older persons)
2. have a diagnosis of chronic (persistent) AF, whether new or pre-existing, irrespective of the antithrombotic therapy prescribed at the time of recruitment
3. provide informed written consent to participate in the study, including telephone follow-up

Exclusion Criteria

GPs:
1. not practicing in one site (i.e., general practice surgery across multiple sites or surgeries)
2. not practicing in the specified Divisions of General Practice
3. do not provide informed written consent to participate in the study

Patients:
1. aged < 65 years
2. do not have a diagnosis of chronic (persistent) AF
3. do not provide informed written consent to participate in the study, including telephone follow-up

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
changes to antithrombotic therapy (initiations, changes, cessations) made by GPs following application of CARAT.[0, 1, 6, 12 months];difference in the proportion of patients receiving antithrombotic therapy and those receiving no therapy at all.[0, 1, 6, 12 months];difference in the proportion of patients experiencing adverse clinical outcomes (ALL events). [0, 1, 6, 12 months]

Secondary Outcome Measures

Name	Time	Method
the sustainability of prescribed therapy over time, i.e., changes to antithrombotic therapy made during patient follow-up over 12 months. [0, 1, 6, 12 months];incidence of any clotting (thromboembolism, stroke) and bleeding (minor or major haemorrhage) events over 12 months. <br>[0,1, 6, 12 months];Health related quality of life (using SF-36 Health Survey). <br>[0, 12 months<br>]